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(GVHD) was uncertain.
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532 C.-H. Wang et al.December 2013) during the early neutropenic phase (until engraftment), were retrospectively
reviewed.
Results: There were 52 allo-HSCT recipients, two of whom were younger than 18 years of age.
Twelve cases received posaconazole and 40 cases received fluconazole as primary antifungal
prophylaxis. The two groups had similar transplant characteristics, conditioning, and GVHD
prophylaxis regimens. The fluconazole group had a higher risk for development of invasive
fungal infections within 90 days after allo-HSCT (43% vs. 8.3%, pZ 0.039). KaplaneMeier anal-
ysis indicated that the cumulative incidence of invasive fungal infection for 90 days after allo-
HSCT was higher in the fluconazole group (log rank test, p Z 0.047). Early discontinuation of
antifungal prophylaxis for intolerance was significantly lower in the posaconazole group (8.3%
vs. 50%, p Z 0.017). Both groups had similar rates of impaired liver function.
Conclusion: Analysis of primary fungal prophylaxis during the early neutropenic phase
following allo-HSCT indicated that posaconazole was more effective and was better tolerated
than fluconazole. Both drugs had similar safety profiles.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Recipients of allogeneic blood hematopoietic stem cell
transplantation (allo-HSCT) who experience invasive fungal
infections tend to have an unfavorable outcome.1,2 Thus,
many clinicians recommend prophylactic antifungal agents
for such patients.3,4 Reduction of all-cause mortality,
fungal infection-related mortality, and documented inva-
sive fungal infections and overall need for empiric anti-
fungal treatment compared to the placebo were
reported.5e8Many studies have recommended fluconazole
for antifungal prophylaxis, because this drug reduces the
incidence of invasive Candida infections and improves the
overall outcome of allo-HSCT recipients.4,9,10
Following the widespread implementation of antifungal
prophylaxis with fluconazole, the epidemiology of invasive
fungal functions has changed and currently, invasive
aspergillosis is the most common invasive fungal infection
in HSCT recipients.11 Recent systemic reviews that
compared prophylaxis with mold-active agents (with anti-
Aspergillus activity) and fluconazole (without anti-Asper-
gillus activity) indicated that mold-active agents more
effectively reduced invasive fungal infections and invasive
fungal infection-related mortality in patients undergoing
HSCT.12,13 Posaconazole is a new-generation triazole oral
suspension with an extended spectrum of antifungal activ-
ity. This drug has activity against Candida spp., Aspergillus
spp., Zygomycetes, and Fusarium spp.,14 and has been
approved for antifungal prophylaxis in patients with neu-
tropenia following chemotherapy and for graft-versus-host
disease (GVHD) after allo-HSCT.15,16
Fluconazole has been used in our hospital since 1999 for
primary antifungal prophylaxis in allo-HSCT recipients.
Posaconazole was introduced to our hospital in 2011, and
was substituted for fluconazole for primary antifungal
prophylaxis in allo-HSCT recipients since June 2011, based
on recent new evidence available.15,16We conducted a
retrospective study comparing the efficacy and safety of
antifungal prophylaxis in allo-HSCT recipients during the
initial neutropenic phase with posaconazole (from June
2011 to December 2013) and fluconazole (from January
2005 to June 2011) in our hospital.Methods
Study design
This investigation was a retrospective study conducted at
Tri-Service General Hospital, National Defense Medical
Center, a 1700-bed acute-care teaching hospital in Taipei,
Taiwan. All patients who received allo-HSCT in the HSCT
room at this institution and were given prophylactic oral
posaconazole (from June 2011 to December 2013) or flu-
conazole (from January 2005 to June 2011) were included.
The study was approved by the Institutional Review Board
of the hospital (TSGHIRB approval number: 1-103-05-015).
Patients with active infections at the time of HSCT, those
who received secondary antifungal prophylaxis, and those
who received prophylaxis from an agent other than flu-
conazole or posaconazole were excluded. The observation
period began at the time of antifungal prophylaxis at the
beginning of conditioning (7 days prior to HSCT) and ended
90 days after allo-HSCT. The demographic and clinical
characteristics of patients and their outcomes were
retrieved by medical chart review.Patient care
The standards for maintaining protective environments did
not change significantly throughout the study period. Dur-
ing the HSCT course, all patients stayed in a single room
that had high efficiency particulate air filters with period-
ical fallout testing (every 5000 hours), and water supplied
to the HSCT room after reverse osmosis and particulate
filtration with periodical water monitoring. There were no
new construction processes during the study period. Other
measures included standard precautions for hand, skin, and
oral hygiene, and diets with a low microbial content.
Baseline biochemistry and routine blood tests were
recorded prior to allo-HSCT. Hickman catheter implantation
was performed before initiation of the conditioning
regimen for drug infusion and parental nutrition. The
catheter was removed before discharge or when a catheter-
related infection occurred. Transfusion of blood, platelets,
Posaconazole vs. fluconazole in transplantation 533and granulocyte colony-stimulating factor were based on
clinical decisions for individual patients. All patients
received acyclovir (prophylaxis for herpes simplex virus and
cytomegalovirus) after initiation of the conditioning
regimen until engraftment.
Antifungal prophylaxis consisted of oral fluconazole
tablets (100e400 mg once/day) or an oral suspension of
posaconazole (200 mg three times/day), given from 7 days
prior to HSCT until engraftment or occurrence of neu-
tropenic fever that required change to another broad-
spectrum antifungal agent. Bacterial prophylaxis with oral
levofloxacin and neomycin for digestive decontamination
was given from 7 days prior to HSCT until engraftment or
occurrence of a neutropenic fever that required change to
a broad-spectrum antimicrobial agent. Engraftment was
considered when absolute neutrophil counts were >500/mL
after the nadir absolute count.17 Neutropenic fever was
defined as an oral temperature >38.3C and an absolute
neutrophil count <500/mL. Patients with febrile neu-
tropenia were given chest radiography, and their urine,
sputum, and blood were collected for culturing. High-
resolution computed tomography (CT) of the thorax was
performed if the chest plain film indicated a new or pro-
gressive lung lesion. Abdominal sonography was performed
if clinical symptoms and signs suggested an intra-abdominal
infection. Administration of empiric broad-spectrum anti-
microbial agents was in accordance with the guidelines of
the Infectious Diseases Society of America (IDSA), as
determined by an infectious disease specialist.18 An empiric
parenteral broad-spectrum antifungal agent was adminis-
trated if a fever lasted 72e96 hours after initiation of a
broad-spectrum antimicrobial agent, or if clinical charac-
teristics suggested an invasive fungal infection based on
assessment by two infectious disease specialists and one
hematologist. Tests for galactomannan and (1-3)-b-d-
glucan were not available during the study period.Outcome measurements
The primary efficacy measure was the incidence of break-
through invasive fungal infection for 90 days after allo-
HSCT. Invasive fungal infections included those that were
suspected, possible, probable, or proven. Possible, prob-
able, or proven invasive fungal infections were defined by
the 2008 criteria of the European Organization for Research
and Treatment of Cancer (EORTC).19 Suspected invasive
fungal infection was defined as an unexplained persistent
fever that lasted 72e96 hours during the neutropenic phase
(despite use of broad-spectrum antibacterial therapy), or
clinical characteristics suggested an invasive fungal infec-
tion that required initiation of parenteral broad-spectrum
antifungal therapy.17All suspected fungal infections based
on assessments by two infectious disease specialists (on
duty infectious disease specialists and reevaluated by
N.C.W. or T.Y.L., who were infectious disease specialists
who specialized in fungal infections) and one hematologist
(T.Y.C., W.Y.K., C.L.H., Y.C.C., M.S.D., P.Y.C., and Y.Y.W.
were involved in helping the diagnosis of invasive fungal
diseases during the study period).
We also assessed the incidence of neutropenic fever and
overall mortality at 90 days after allo-HSCT, which wasdefined as death for any reasons during 90 days after HSCT.
All adverse clinical and laboratory events related to the use
of antifungal agents during the prophylaxis period,
including gastrointestinal effects and liver function
impairment, were recorded. Hepatic toxicity was analyzed
by measurement of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and total bilirubin levels
during the prophylaxis period.
Statistical analysis
The results were analyzed using a commercially available
software package (SPSS version 16.0; SPSS Inc., Chicago, IL,
USA). Categorical variables were analyzed using the Chi-
square test or Fisher’s exact test as appropriate, and
continuous variables were analyzed with the Mann-Whitney
U test. The Wilcoxon matched-pairs signed-rank test was
used to compare safety parameters, and levels of ALT, AST,
and bilirubin at baseline and maximum. Kaplan-Meier
curves were used to present the cumulative incidence of
invasive fungal infections for 90 days post-HSCT, and curves
were compared using the log-rank test. All p values were 2-
tailed and p < 0.05 was considered statistically significant.
Results
Patient characteristics
Table 1 summarizes the demographic and clinical charac-
teristics of the 52 allo-HSCT recipients. Twelve patients
(23%) received oral posaconazole and 40 patients (77%)
received oral fluconazole for primary prophylaxis. The
overall median patient age was 30 years, and two patients
were younger than 18 years (9 years and 16 years, respec-
tively). The most common underlying diseases overall were
acute myeloid leukemia (n Z 19) and acute lymphoblastic
leukemia (n Z 17). The transplantations were mostly from
matched family donors (n Z 27) and matched unrelated
donors (n Z 20). Most stem cells were from peripheral
blood (n Z 51). Twenty-four patients (46%) developed
GVHD during the 90 days after allo-HSCT, but all GVHD
cases developed after engraftment. Among patients who
received oral fluconazole, the daily doses were 100 mg
(n Z 34), 200 mg (n Z 2), and 400 mg (n Z 4). The two
groups had no significant differences in any of the
measured clinical and demographic characteristics, and
also had similar conditioning regimens and GVHD prophy-
laxis regimens. Both groups also had a similar median in-
terval from transplantation to engraftment (16.0 days
vs.17.5 days, p Z 0.238), rates of acute Grade 1e2 GVHD
(25.0% vs. 35.0%, pZ 0.729), and rates of acute Grade 3e4
GVHD (8.3% vs. 15.0%, p Z 1.000).
Efficacy and safety analysis
The efficacy and safety outcomes are shown in Table 2.
Analysis of fungal infections indicated that the fluconazole
group had a greater risk for development of invasive fungal
infection than theposaconazole groupduring the90days after
allo-HSCT (42.5% vs. 8.3%, pZ 0.039). In agreement with this
Table 1 Demographic and clinical characteristics of patients receiving allogeneic blood hematopoietic stem cell trans-
plantation with prophylactic fluconazole or posaconazole
Variable Posaconazole (n Z 12) Fluconazole (n Z 40) pa All
Age in y, median (IQR) 34.5 (28.0e50.7) 29.5 (23.3e41.8) 0.200 30 (26.2e42.0)
Male sex 8 (66.7) 30 (75.0) 0.712 38 (73.0)
Primary diagnosis
Lymphoma 1 (8.3) 2 (5.0) 0.553 3 (5.7)
Non-lymphoma 11 (91.7) 38 (95.0) 49 (94.3)
Aplastic anemia 2 (16.7) 5 (12.5) 0.656 7 (13.5)
Acute myeloid leukemia 6 (50.0) 13 (32.5) 0.317 19 (36.5)
Acute lymphoblastic leukemia 2 (16.7) 15 (37.5) 0.294 17 (32.7)
Myelodysplastic syndrome 1 (8.3) 2 (5.0) 0.553 3 (5.8)
Chronic myeloid leukemia 0 (0) 3 (7.5) 1.000 3 (5.8)
Donor type
MUD 7 (58.3) 13 (32.5) 0.175 20 (38.5)
MMUD 0 (0) 5 (12.5) 0.578 5 (9.6)
MFD 5 (41.6) 22 (55.0) 0.517 27 (51.9)
MMFD 0 (0) 0 (0) d 0 (0)
Stem cell source
Peripheral blood 12 (100.0) 39 (97.5) 1.000 51 (98.1)
Umbilical cord blood 0 (0) 1 (2.5) d 1 (1.9)
Total body irradiation 2 (16.7) 16 (40.0) 0.179 18 (34.6)
Condition regimen
Myeloablative 7 (58.3) 30 (75.0) 0.293 37 (71.2)
Reduced intensity 5 (41.7) 10 (25.0) d 15 (28.8)
GVHD prophylaxis regimen
Methotrexate þ cyclosporine 4 (33.3) 25 (62.5) 0.102 29 (55.8)
Methotrexate þ cyclosporine þ ATG 7 (58.3) 14 (35.0) 0.188 21 (40.4)
Othersb 1 (8.3) 1 (2.5) 0.412 2 (3.8)
Acute GVHD
Grade 1e2 3 (25.0) 14 (35.0) 0.729 17 (32.6)
Grade 3e4 1 (8.3) 6 (15.0) 1.000 7 (13.5)
Time to engraftment, median (IQR) 16.0 (15.0e20.3) 17.5 (15e22.3) 0.238 17 (15.0e21.0)
a Comparison of the posaconazole and fluconazole groups.
b Methotrexate þ cyclosporine þ tacrolimus.
Data are presented as n (%), unless otherwise indicated.
ATG Z antithymocyte globulin; GVHD Z graft-versus-host disease; IQR Z interquartile range; MFD Z mismatched family donor;
MMFD Z mismatched family donor; MMUD Z mismatched unrelated donor; MUD Z matched unrelated donor.
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invasive fungal infection for 90 days after allo-HSCT indicated
a higher cumulative incidence in the fluconazole group (log
rank test, p Z 0.047; Fig. 1). Among the fluconazole group,
patients receiving a higher dose fluconazole (200e400 mg/
day) had similar incidences of breakthrough invasive fungal
infections compared to those receiving a lower dose
(100 mg day; 50.0% vs.41.2%, pZ 1.000).
Among the 17 patients who developed invasive fungal
infections in the fluconazole group, 13 patients had sus-
pected fungal infections. One patient had a possible fungal
infection as hepatic candidiasis, based on the presence of
multiple nodules in the liver in the neutropenic phase after
allo-HSCT (14 days after allo-HSCT), two patients had
possible fungal infections of the lung based on the typical
“halo sign” in the high resolution chest CT after engraft-
ment associated with fever and respiratory symptoms (48
and 82 days after allo-HSCT), and one patient had a proven
fungal infection as candidemia due to Candida tropicalis,
which is not susceptible to fluconazole in the neutropenic
phase after allo-HSCT (20 days after allo-HSCT). Bycontrast, only one case in the posaconazole group devel-
oped a suspected fungal infection.
Both groups had similar rates of neutropenic fever
(83.3% vs. 87.5%, pZ 0.656) and mortality (8.3% vs. 22.5%,
pZ 0.420) at 90 days after allo-HSCT. The one death in the
posaconazole group was due to cytomegalovirus pneumo-
nitis. One of the nine deaths in the fluconazole group was
due to cytomegalovirus pneumonitis, one death was due to
urinary tract infection by Klebsiella pneumoniae, four
deaths were due to pneumonia by Acinetobacter bau-
mannii, Serratia marcescens, Enterobacter cloacae, and
Pseudomonas aeruginosa, respectively, two deaths were
due to primary blood stream infections by Escherichia coli,
and one death was due to a possible fungal infection.
The rate of early discontinuation of antifungal agents due
to intolerance was significantly lower in the posaconazole
group than the fluconazole group (8.3% vs. 50.0%, pZ 0.017).
No patients in either group discontinued antifungal agents
due to impairment of liver function. One patient experi-
enced intolerance to posaconazole (refractory nausea and
vomiting) and 20 patients was intolerant to fluconazole due
Table 2 Safety and efficacy outcomes in patients receiving antifungal prophylaxis after allogeneic blood hematopoietic stem
cell transplantation with prophylactic fluconazole or posaconazole
Variable Posaconazole
(n Z 12)
Fluconazole
(n Z 40)
pa All (n Z 52)
Efficacy outcome
Invasive fungal infection 1 (8.3) 17 (42.5) 0.039 18 (34.6)
Suspected 1 (8.3) 13 (32.5) 0.144 14 (26.9)
Possible 0 (0) 3 (7.5) 1.000 3 (5.8)
Probable 0 (0) 0 (0) d 0 (0)
Proven 0 (0) 1 (2.5) 1.000 1 (1.9)
Neutropenic feverb 10 (83.3) 35 (87.5) 0.656 45 (86.5)
90-d mortality after allogeneic
blood hematopoietic stem
cell transplantation
1 (8.3) 9 (22.5) 0.420 10 (19.2)
Clinical and laboratory adverse
events
Early discontinuation due to
intolerance
1 (8.3) 20 (50.0) 0.017 16 (30.7)
Nausea and vomiting 5 (41.7) 23 (57.5) 0.510 28 (53.8)
Diarrhea 4 (33.3) 28 (70.0) 0.040 32 (61.5)
Increase in total bilirubin levelc 1 (8.3) 10 (25.0) 0.421 11 (21.2)
Increase in alanine
aminotransferase leveld
7 (58.3) 17 (42.5) 0.510 24 (46.2)
Increase in aspartate
aminotransferase levele
1 (8.3) 7 (17.5) 0.630 8 (15.4)
a Comparison of the posaconazole and fluconazole groups.
b Temperature >38.3C and absolute neutrophil count <500/mL.
c Total bilirubin >2 mg/dL (normal upper limit: 1.3 mg/dL).
d Alanine aminotransferase >82 U/L (normal upper limit: 41 U/L).
e Aspartate aminotransferase >80 U/L (normal upper limit: 40 U/L).
Data are presented as n (%).
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tablets. Both groups had similar rates of gastrointestinal
symptoms (nausea and vomiting; pZ 0.510), but patients in
the fluconazole group were more likely to develop diarrhea
than those in the posaconazole group (p Z 0.040). In the
fluconazole group, patients receiving a higher dose
(200e400 mg/day) were more likely to discontinue prophy-
laxis early for intolerance than those receiving a low dose
(100mg/day; 83.3% vs.44.1%, pZ 0.182) although statistical
significance was not observed.
Fig. 2 shows the levels of AST, ALT, and total bilirubin in
the two groups before treatment and the maximal
measured values during the prophylaxis period. Both groups
had significant increases in all three parameters (pos-
aconazole group: p Z 0.002, p Z 0.002, and p Z 0.02,
respectively; fluconazole group: p < 0.001, p < 0.011, and
p < 0.001, respectively). There were no significant differ-
ences in impairment of liver function in the two groups
(Table 2). Only four patients (1 in the posaconazole group
and 3 in the fluconazole group) did not have normalization
of liver function after discontinuation of the prophylactic
antifungal agents.Discussion
The present research is the first study to compare primary
antifungal prophylaxis with posaconazole and fluconazoleduring the early neutropenic phase after allo-HSCT in pa-
tients from Taiwan. Our results indicate that posaconazole
was associated with better efficacy and tolerance, and had
similar safety as fluconazole.
More aged patients with an insignificantly different dis-
tribution of underlying diseases and conditioning regimens
in the posaconazole group compared to the fluconazole
group were noted during the study period. This evolution
change on transplantation features may confound our
analysis on antifungal prophylaxis. The change in trans-
plantation features during the two study periods in our
study reflected medical care improvement in Taiwan in
transplantation fields. Therefore, more aged and compli-
cated patients were eligible to receive transplantation,
which provided clinicians with more challenges.
Among mold active agents, posaconazole was reported
to have better efficacy in reduction of fungus infection and
mortality related to fungal infection primarily focused on
patients with GVHD after HSCT and patients with myelo-
dysplastic syndromes or acute myeloid leukemia undergo-
ing chemotherapy.15,16,20 In contrast to these previous
studies, our study examined allo-HSCT recipients who
received posaconazole or fluconazole during the early-
neutropenic phase until engraftment, before development
of GVHD. In addition, because of the unavailability of gal-
actomannan and (1-3)-b-d-glucan testing and the difficulty
in performing invasive diagnostic procedures for histopa-
thology in such patients to aid in diagnosis, we used the
Figure 1. Time to invasive fungal infection after allogeneic blood hematopoietic stem cell transplantation in patients given
prophylactic fluconazole or posaconazole. The cumulative incidence of invasive fungal infection was 34.6% overall, and was 42.5%
in the fluconazole group and 8.3% in the posaconazole group (p Z 0.047, log-rank test). allo-HSCT Z allogeneic blood hemato-
poietic stem cell transplantation.
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tients with unexplained persistent neutropenic fever, as in
most other medical centers in Taiwan. To reflect the situ-
ation in clinical practice, we defined suspected fungal
infection as previously reported plus assessments by two
different infectious diseases doctors and one hematologist
and added to our efficacy analysis.17Our results showed
that posaconazole prophylaxis was more effective than
fluconazole prophylaxis in the reduction of invasive fungal
infections in this clinical setting, although the two groups
had similar 90-day mortalities after allo-HSCT. In agree-
ment with our results, another study that compared pos-
aconazole and itraconazole in allo-HSCT recipients in the
early neutropenic phase without GVHD, also showed supe-
rior efficacy of posaconazole.21 However, our study and this
previous study both had small sample sizes and retrospec-
tive designs. In addition, most patients in our study
received low dose fluconazole (100 mg/day) rather than
400 mg/day recommended by IDSA guidelines,22 which
might result in breakthrough infection and failure in
prophylaxis.23 Therefore, it may confound analysis on effi-
cacy between the groups in our study. Thus, further ran-
domized prospective studies with large sample sizes
comparing the recommended dose of fluconazole are
needed to confirm the superiority of posaconazole in this
clinical setting.
Assessment of the benefits of prophylactic antifungal
therapy should also consider adverse drug effects. Our re-
sults provide further evidence for the tolerance and safety
of posaconazole and fluconazole. Both groups had nosignificant differences in impairment of liver function. In
particular, both groups had transient and moderate eleva-
tions of ALT, AST, and bilirubin, and the levels of these
parameters returned to the normal ranges after discontin-
uation of antifungal agents in most patients. None of our
patients discontinued prophylactic antifungal agents due to
liver impairment. Among the four patients whose liver
function did not return to normal, three patients subse-
quently developed Grade 3e4 GVHD, and one patient
developed Grade 2 GVHD. Therefore, unresolved hepatitis
after discontinuation of antifungal agents may be an early
presentation of GVHD. In addition, more patients in the
fluconazole group switched to parenteral fluconazole (due
to mucositis, making pill swallowing difficult) and more
patients in the fluconazole group developed diarrhea.
Therefore, the rate of early discontinuation of antifungal
agents due to intolerance was lower in the posaconazole
group, suggestive of better tolerance for posaconazole in
this clinical setting.
There were a few limitations in our study. This study was
retrospective and patients in the two groups were
compared during different periods of time. Changes in daily
care to patients not recorded in the medical charts and
different transplantation features in patients between the
two periods may confound analysis in our study. The lack of
galactomannan and (1-3)-b-d-glucan tests in our center may
have led to an underestimate of the number of probable
fungal infections. Suspected invasive fungal infections in
our study assessed by different infectious disease special-
ists and hematologist may have led to diagnosed bias.
Figure 2. Hepatotoxicity in patients receiving allogeneic blood hematopoietic stem cell transplantation with prophylactic flu-
conazole or posaconazole. Box plots show liver parameters (A, alanine aminotransferase; B, aspartate aminotransferase; and C, total
bilirubin) the day before initiation of antifungal therapy and the maximum values during antifungal therapy. Wilcoxon matched-pair
signed-rank tests indicated significant differences in all three parameters for each group. *p < 0.05 for all comparisons.
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small, which may have led to an underestimate in the dif-
ference of demographics between the two groups.
In conclusion, although our study was retrospective and
the sample size was small, this is the first reported com-
parison analysis between prophylactic posaconazole and
fluconazole in patients who received allo-HSCT in a real-
world setting in Taiwan. The results showed that antifungal
prophylaxis with posaconazole in allo-HSCT patients during
the early engraftment phase provided better efficacy in
reducing the incidence of invasive fungal infections, better
tolerance, and a similar safety when compared with flu-
conazole. Additional prospective studies with larger sample
sizes are needed to validate the superiority of posaconazole
in this clinical setting.
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